Boehringer Ingelheim, recognized globally in the field of animal health, has introduced the first FDA-approved oral VETMEDIN Solution specifically designed to address congestive heart failure (CHF) stemming from MMVD or DCM in dogs.
Heart disease is unfortunately prevalent in canines, impacting nearly 10% at some point in their lifespan. The primary causes are often myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), which can advance to CHF, compromising the heart’s ability to circulate blood efficiently.
Pet owners now have a convenient, innovative option to manage CHF in dogs: a liquid form of VETMEDIN, a leading medication in canine cardiology worldwide. Research has already demonstrated that VETMEDIN can enhance both survival duration and life quality in dogs suffering from MMVD or DCM.
“Our goal is to consistently provide new solutions that are backed by solid clinical evidence to assist more pets,” stated Daniel Watkins, VP of the US Pet Business at Boehringer Ingelheim. “We understand that some dogs and their owners might prefer a liquid medication format, particularly for smaller breeds. With the VETMEDIN Solution, a straightforward liquid formula, we can better support dogs with heart diseases, helping them live longer and healthier lives.”
Now accessible in the US, VETMEDIN Solution offers the same dual-action benefits as the VETMEDIN chewable tablets. The tasteless oral liquid solution is administered directly into the dog’s mouth twice daily.
Since its inaugural release 25 years ago, VETMEDIN has granted dogs and their owners over a million additional years together. The chewable tablets are authorized for managing the symptoms of mild to severe CHF due to MMVD or DCM with concurrent therapies, such as furosemide, on a tailored basis.
Additionally, Boehringer Ingelheim provides VETMEDIN-CA1 (pimobendan), an FDA conditionally approved treatment for dogs in Stage B2 preclinical MMVD, potentially postponing the onset of heart failure symptoms.
Boehringer Ingelheim is committed to offering cutting-edge solutions to prevent and treat animal diseases, delivering a vast array of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governing bodies.
Operating within both human and animal health sectors, Boehringer Ingelheim stands as a significant industry contributor to research and development, creating breakthrough therapies for critical unmet health needs.